Summary

Intravenous recombinant tissue plasminogen activator (tPA) is recommended for the treatment of acute ischemic stroke within the first 3 hours of stroke onset. The objective of the Echoplanar Imaging Thrombolytic Evaluation Trial [EPITHET] was to evaluate the effect of the administration of tPA 3–6 hours after stroke onset as measured by echoplanar magnetic resonance imaging (MRI), diffusion-weighted MRI, and perfusion-weighted MRI.